Page last updated: 2024-09-05

lenalidomide and Hemolysis

lenalidomide has been researched along with Hemolysis in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Barcellini, W; Cortelezzi, A; Fattizzo, B; Nesa, F; Sciumbata, VM; Zanella, A; Zaninoni, A	1
Sofronescu, AG; Wedel, W	1

Other Studies

2 other study(ies) available for lenalidomide and Hemolysis

Article	Year
Lessons from very severe, refractory, and fatal primary autoimmune hemolytic anemias. American journal of hematology, 2015, Volume: 90, Issue:8 Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Erythrocytes; Hemolysis; Humans; Immunologic Factors; Lenalidomide; Plasma Exchange; Rituximab; Severity of Illness Index; Splenectomy; Steroids; Thalidomide; Time-to-Treatment; Treatment Outcome	2015
Transiently Pink-Tinged Serum in a Patient With Multiple Myeloma and Anemia Undergoing Lenalidomide Treatment. American journal of clinical pathology, 2015, Volume: 144, Issue:2 Topics: Anemia; Antineoplastic Agents; Female; Hemolysis; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Thalidomide	2015

Article

Year

Lessons from very severe, refractory, and fatal primary autoimmune hemolytic anemias.

American journal of hematology, 2015, Volume: 90, Issue:8

Topics: Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal, Murine-Derived; Erythrocytes; Hemolysis; Humans; Immunologic Factors; Lenalidomide; Plasma Exchange; Rituximab; Severity of Illness Index; Splenectomy; Steroids; Thalidomide; Time-to-Treatment; Treatment Outcome

2015

Transiently Pink-Tinged Serum in a Patient With Multiple Myeloma and Anemia Undergoing Lenalidomide Treatment.

American journal of clinical pathology, 2015, Volume: 144, Issue:2

Topics: Anemia; Antineoplastic Agents; Female; Hemolysis; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Thalidomide

2015